Pregnancy-associated plasma protein-A and -A2 (PAPPA and PAPPA2) are proteases that cleave IGF binding proteins (IGFBPs) and thereby increase the bioavailability of growth factors. PAPPA has long been recognized as a marker of fetal genetic disorders and adverse pregnancy outcomes. In contrast, although PAPPA2 is also highly expressed in human placenta, its physiological importance is not clear. To establish whether mice will be a useful model for the study of PAPPA2, we compared the patterns of expression of PAPPA2 in the placentae of mouse and human. We show, for the first time, that Pappa2 is highly expressed in mouse placenta, as is the case in humans. Specifically, it is expressed at the interface of the maternal and fetal layers of the mouse placenta at all gestational stages studied (10 . [5][6][7][8][9][10][11][12][13][14][15][16] . 5 days post coitum).
Introduction
The placenta acts as the interface between fetus and mother during gestation (Cross et al. 1994) . Abnormal placental development leads to serious consequences for both fetal and maternal health, such as intrauterine growth restriction (IUGR; Jackson et al. 1995 , Salafia et al. 1995 , and preeclampsia (Redman & Sargent 2005) . During the formation of the placenta in primates and rodents, the epithelium of the uterus is eroded by embryonic trophoblasts, which eventually leads to direct contact between maternal blood and fetal trophoblastic villi, facilitating efficient diffusion between maternal and fetal blood (Rossant & Cross 2001) . The invasive action of trophoblasts is promoted by growth factors, the bioavailability of which is aided by proteases (Lala & Hamilton 1996 , Salamonsen 1999 . One of the critical proteases involved in normal placental development is pregnancy-associated plasma protein-A (PAPPA; Sun et al. 2002) , which is produced by human trophoblasts (Tornehave et al. 1984) where it is the major proteolytic enzyme cleaving insulin-like growth factor binding protein-4 (IGFBP4; Boldt & Conover 2007 ).
Degradation of IGFBP4 by PAPPA leads to the release of insulin-like growth factor II (IGF-II; Giudice et al. 1998 Giudice et al. , 2002 , which promotes the development of the placenta through its positive influence on trophoblast invasion as well as growth and permeability of this highly specialized organ (Constancia et al. 2002) . Moreover, PAPPA is secreted into the maternal circulation (Folkersen et al. 1981) , and can be a useful marker for certain diseases and pregnancy complications. For example, unusually low levels of PAPPA in the first trimester may be indicative of increased risk of fetal genetic disorders such as Down's syndrome (Brambati et al. 1993) and Cornelia de Lange syndrome (Aitken et al. 1999) . Furthermore, low circulating PAPPA levels are also associated with higher risk of low birth weight, IUGR, and preeclampsia , Kwik & Morris 2003 , Dugoff et al. 2004 , Spencer et al. 2008 , which are characterized by impaired trophoblast invasion. Although PAPPA is highly expressed in human placenta (Tornehave et al. 1984) , this is not the case in the mouse (Qin et al. 2002 , Soe et al. 2002 . Nevertheless, Pappa plays an important role in fetal development as Pappa-deficient mice show delayed and impaired growth ).
Recently, another protease similar to PAPPA has been identified (Farr et al. 2000 , Overgaard et al. 2001 , Page et al. 2001 and designated as PAPPA2 (earlier names included PAPP-E and Plac3). Like PAPPA, PAPPA2 is abundantly expressed in the human placenta (Farr et al. 2000 , Page et al. 2001 , and also cleaves an IGFBP (Overgaard et al. 2001) . Unlike PAPPA, which proteolyses both IGFBP4 and IGFBP5 (Boldt et al. 2004) , PAPPA2 cleaves IGFBP5 and may also show lower proteolytic activity against IGFBP3 (Overgaard et al. 2001) . Although the physiological functions of PAPPA2 have not been studied, at least four recent studies have found PAPPA2 to be upregulated in hypertensive disorders of pregnancy including preeclampsia and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome (Buimer et al. 2008 , Nishizawa et al. 2008 , Sitras et al. 2009 , Winn et al. 2009 .
Understanding the role of PAPPA2 in placental growth and development may further enhance our knowledge of disorders such as preeclampsia and IUGR and lead to improvements in diagnosis and therapeutic interventions. Animal models are needed to elucidate the physiological roles of PAPPA2 in the placenta in health and disease (Rossant & Cross 2001 , Sapin et al. 2001 , Cross 2003 . Therefore, the primary goal of the current study was to examine and compare the expression and localization of PAPPA2 in mouse and human placentae. A secondary goal was to determine its location of expression in mouse embryo.
Materials and Methods

Sample collection
Mice (Charles River Laboratories, Saint-Constant, Quebec, Canada) were housed in the Animal Care Facility at SFU, and all procedures were in accordance with the guidelines of the Canadian Council on Animal Care. Six CD1 female mice were time-mated with CD1 studs, and the day the seminal fluid plug was found was designated as day 0 . 5 post-coitus (dpc). On 12 . 5 dpc, females were killed by CO 2 inhalation.
Embryos, placentae, stomach, kidneys, and liver were quickly dissected in diethylpyrocarbonate (DEPC)-treated 10!PBS (Nagy et al. 2003) , and these samples were immediately either frozen at K20 8C for protein work, fixed in 4% paraformaldehyde (PFA) overnight for in situ hybridization (placentae and embryos only), or placed in RNAlater (Ambion, Foster City, CA, USA) overnight at 4 8C and then stored at K20 8C prior to quantitative PCR. Nonpregnancy serum samples were collected from live mice from the saphenous vein, and pregnancy serum samples were collected from killed mice by cardiac puncture. Blood samples were centrifuged, and serum was collected and stored at K80 8C until further use.
Serum samples were also obtained from three healthy nonpregnant women, three healthy pregnant women during the first trimester, and three at term. This study was approved by The Ottawa Hospital Research Ethics Board, and informed consent was obtained. Upon collection, samples were centrifuged and the serum frozen at K20 8C for later batch analysis. Early placental tissues were obtained from voluntary terminations at 8-12 weeks.
RNA isolation and quantitative PCR
Quantitative PCR was performed to compare expression levels of Pappa2 and Pappa transcripts. Total RNA was extracted from mouse tissues using QIAshredder homogenizers (Qiagen) and RNeasy spin columns (Qiagen) following the manufacturer's instructions. Each sample was standardized to contain 50 ng/ml total RNA, and a reference sample was prepared by combining aliquots of placental samples; this reference sample was included in every assay to account for variation between assays. The relative expression levels of Pappa2 and Pappa in the tissue samples and reference sample were assessed by quantitative PCR with the MJ Mini Thermal Cycler (Bio-Rad) using primers and probes (Integrated DNA Technologies, Coralville, IA, USA) as described in Table 1 . The expression of a 'housekeeping gene', b-actin (Actb, as given in MGI Database), was also measured. All primers were designed to span introns to avoid detection of genomic DNA. iScript One-Step RT-PCR Kit for Probes (Bio-Rad) was used to reverse-transcribe and amplify the RNA template for 40 cycles, and the cycle at which the signal rose above a fixed threshold (C t ) was determined. The quantitative PCR amplification was performed using 25 ml reaction volumes containing reaction mix (Bio-Rad), Protector RNase Inhibitor (Roche Applied Sciences), 0 . 5 U iScript RTase, 8 . 5 ml RNA template (i.e. 425 ng), 0 . 25 mM each primer, and 175 nM probe. The quantitative PCR program consisted of an initial reverse transcription of 30 min at 50 8C, an initial PCR activation step of 15 min at 95 8C followed by 40 cycles of 1 min at 94 8C, 1 min at 55 8C, and 1 min at 72 8C.
Samples were measured in triplicate and the C t values for Pappa2 and Pappa were normalized to those of b-actin using 
the Pfaffl method (2001), which involves calculating the efficiency of the PCR for each gene using serial dilutions of samples. Using this method, expression in a sample is calculated relative to the reference sample measured in the same assay to account for variation between assays. In order to compare transcript levels between Pappa2 and Pappa, we estimated transcript copy number using a standard curve constructed for each gene. cDNA samples corresponding to the regions amplified during quantitative PCR were generated with a One-Step RT-PCR Kit (Qiagen). The DNA concentration of each cDNA sample was measured using a NanoDrop spectrometer, and cDNA copy number was calculated using cDNA concentration and amplicon length (http://www.uri.edu/research/gsc/resources/cndna.html). cDNA samples were then serially diluted and used as template for quantitative PCR to construct the standard curves.
Western blotting
Mouse tissue samples were homogenized in T-PER Tissue Protein Extraction Reagent (Pierce, Rockford, IL, USA) and incubated on ice for 15 min to allow cell lysis. The homogenates were then centrifuged at 16 000 g and supernatant collected and stored at K80 8C until further use. Complete Protease Inhibitor Cocktail (Roche Applied Sciences) was added to all samples (including serum samples) to prevent protein degradation.
Samples containing 30 mg total protein were mixed with 5!SDS loading buffer and boiled for 10 min. Samples and pre-stained molecular weight markers (Precision Plus Protein Prestained Standards, Bio-Rad) were loaded onto a 4% stacking gel and run through an 8% polyacrylamide gel under reducing conditions. The gels were then equilibrated in transfer buffer, and proteins were transferred onto nitrocellulose membranes (Bio-Rad) using a semi-dry transfer machine (Bio-Rad). After transfer, the membranes were rinsed, blocked, and then incubated overnight at 4 8C with 1:1000 polyclonal anti-human PAPPA2 antibody (R&D Systems, Minneapolis, MN, USA). According to the manufacturer, this antibody shows !1% cross-reactivity with PAPPA. Membranes were washed, incubated with 1:10 000 fluorescent-labeled secondary antibody (Li-Cor Biosciences, Lincoln, NE, USA) for 45 min at room temperature, rinsed and scanned with an Odyssey infrared imaging system (Li-Cor Biosciences).
For western blotting of human serum, 0 . 5 ml aliquots of serum samples were resolved using 7 . 5% SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes in duplicate. The two membranes were immunoblotted with anti-human PAPPA and PAPPA2 antibodies (R&D Systems), and the bands were visualized using ECL reagents (Thermo Fisher Scientific, Rockford, IL, USA). To confirm the specificity of the PAPPA2 antibody, a recombinant PAPPA2 peptide (amino acids 243-1396; R&D Systems) was included in the gel as a positive control. Furthermore, an additional membrane was blotted with nonpregnant and pregnant serum samples, which were probed with a secondary antibody (HRP conjugated rabbit anti-goat IgG, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) without incubation with PAPPA2 antibody.
Immunohistochemistry
Cross sections of mouse placenta at different stages of pregnancy were obtained from Zyagen (San Diego, CA, USA). Slides were deparaffinized in xylene washes and rehydrated with graded series of ethanol. Antigen retrieval was performed by heating the slides in a microwave for 15 min in citrate buffer (pH 6 . 0). Sections were then incubated in PBS with 3% H 2 O 2 for 10 min to inactivate endogenous peroxidase. Blocking steps were performed using serum blocking reagent G, avidin blocking reagent, and biotin blocking reagent (R&D Systems), followed by incubation with polyclonal anti-human PAPPA2 or polyclonal anti-mouse IGFBP5 antibody (1:50, R&D Systems) in PBS overnight at 4 8C. After three washes in PBS, samples were incubated with biotinylated secondary antibody (R&D Systems) for 30 min at 37 8C, followed by streptavidin conjugated with HRP, and visualized with 3,3-diaminobenzidine (DAB) substrate (R&D Systems). The slides were then counterstained with hematoxylin. To evaluate the extent of nonspecific immunostaining, primary antibodies were substituted with goat anti-rabbit IgG (1:50; Sigma) as negative controls.
Human placental samples were fixed overnight in 4% PFA-PBS, dehydrated through a graded series of ethanol, and then embedded in paraffin. Adjacent sections (4-5 mm) were deparaffinized in xylene, followed by rehydration in graded series of ethanol concentrations. Sections were washed with PBS and exposed to 15 min of antigen retrieval (400 ml 10 mM citrate buffer, pH 6 . 0) in the microwave. The inactivation of endogenous peroxidase was performed by the incubation of sections in 3% H 2 O 2 with methanol, followed by blocking solution (50 ml) at room temperature. Adjacent sections were then incubated at 4 8C with primary antibody, polyclonal anti-human PAPPA2 antibody (R&D Systems) in 1!PBS. Biotinylated secondary antibodies were applied to samples for 30 min followed by streptavidin-HRP incubation (40 min) at room temperature. Sections were visualized with DAB or 3-amino-9-ethylcarbazole (AEC) under the light microscope. Counterstaining was performed with hematoxylin stain and sectioned slides were mounted with cytoseal 60. To determine the extent of nonspecific immunostaining, primary antibodies were substituted with goat IgG (at the same concentrations) for negative controls.
To further examine whether extravillous trophoblasts express PAPPA2 at the maternal-fetal interface of human placenta, sections were first stained for cytokeratin 18 (mouse monoclonal antibody, Santa Cruz Biotechnology Inc.), a trophoblast marker, and AEC substrate was used to visualize the immunosignal. After images of typical immunosignals were captured, the sections were destained with 0 . 1 M HCl in 70% ethanol to remove rose-red insoluble precipitates. To remove previously applied antibodies, sections were treated with double stain blocker (DAKO Corporation, Mississauga, Ontario, Canada). Sections were further immunostained for vimentin (goat polyclonal antibody, Santa Cruz Biotechnology Inc.), a marker of maternal decidual cells, or PAPPA2 (R&D Systems). The vimentin and PAPPA2 immunosignals in these sections were examined in the same field as the previously captured image that showed cytokeratin immunoreactivity, which allowed the examination of different immunosignals in the same cells of the same sections.
Probe synthesis for in situ hybridization
Mouse placental mRNA was reverse transcribed into cDNA using the RevertAid H Minus First Strand cDNA Synthesis kit (Fermentas, Burlington, Ontario, Canada), and 600 bp of the Pappa2 gene was amplified using the following primers: 5 0 -CAGAGGGAGGACAGAGCAA-3 0 and 5 0 -GTAAAGG-TGACAGAATCTCAGG-3 0 . The 600 bp cDNA was inserted into TA TOPO cloning vector (Invitrogen) and used as template for in vitro transcription. A 660 bp fragment of the Igfbp5 gene was also amplified (forward primer: 5 0 -ACGAGAAAGCTCTGTCCATGTGTC-3 0 , reverse primer: 5 0 -GCTTCATTCCGTACTTGTCCACAC-3 0 ) and cloned into TA TOPO cloning vector. Similarly, a 434 bp fragment of the Igf-II (Igf2 as listed in MGI Database) gene was produced using the following primers: 5 0 -TTCT-CATCTCTTTGGCCTTCGCCT-3 0 and 5 0 -ACGAT-GACGTTTGGCCTCTCTGAA-3 0 . Antisense and sense probes were synthesized by either SP6 or T7 RNA polymerase depending on insert orientation. Digoxigenin (DIG)-labeled RNA was subsequently purified by Quick Spin Columns (Roche).
Whole-mount in situ hybridization
The brain cavity and heart of mouse embryos were punctured to facilitate exchange of solutions and avoid probe trapping. Embryos were rehydrated by passage through 75, 50, 25% methanol and twice through PBS containing 0 . 1% Tween-20 (PBST). To permeabilize tissues, embryos were treated with 10 mg/ml proteinase K in PBST for 35 min at room temperature, and rinsed briefly in PBST containing 2 mg/ml glycine. Post-fixation was in 4% PFA with 0 . 1% glutaraldehyde for 20 min. After one rinse and one wash in PBST, embryos were equilibrated in 1:1 PBST/hybridization mix at room temperature. Hybridization mix was composed of 50% formamide, pH 5 1 . 3!SSC (Invitrogen), 5 mM EDTA, 50 mg/ml yeast RNA core particle (Sigma), 0 . 2% Tween-20, 0 . 5% CHAPS (Sigma), 100 mg/ml heparin (Sigma) and RNAse-free water, adjusted to pH 8 (Correia & Conlon 2001) . Embryos were pre-hybridized at 65 8C for at least 1 h and hybridized for 36 h at 65 8C with 1 mg/ml of either antisense or sense (for negative controls) DIG-labeled RNA probes. After hybridization, embryos were rinsed twice, followed by two 30-min washes with pre-warmed hybridization buffer at 65 8C. The solution was then replaced by 0 . 1 M maleic acid containing 0 . 1% Tween-20 (MABT) at room temperature. The embryos were incubated in MABT containing 2% Boehringer Blocking Reagent (BBR; Roche) for 1 h at room temperature with gentle shaking, and the solution was replaced with MABT containing 2% BBR and 20% heat-treated goat serum (Sigma) for at least 1 h. The embryos were subsequently incubated with MABTC2% BBRC20% sheep serumC1/5000 dilution of sheep anti-DIG Fab fragment covalently coupled to alkaline phosphatase (Roche) on rotation overnight at 4 8C. The next day, embryos were rinsed three times with MABT, and washed at least five times for 2-4 h each, and incubated overnight with fresh MABT. To visualize probes bound to the embryo, nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) was added to the detection buffer consisting of 100 mM NaCl, 100 mM Tris (pH 9 . 5), and 0 . 1% Tween-20. The embryos were incubated in the solution until color developed. Subsequently, the embryos were rinsed once and washed at least twice with PBST. Embryos were fixed again in 4% PFA/0 . 1% glutaraldehyde for 2 h at room temperature. Embryos were then stored in PBSTC0 . 1% azide at 4 8C (Nagy et al. 2003) .
Results
Expression of Pappa2 measured by quantitative PCR
Pappa transcript levels were not particularly high in mouse placenta compared to other tissues (Fig. 1A) , but Pappa2 expression in the placenta was much higher than in other tissues (Fig. 1B) . For placental samples, the C t values for Pappa ranged from 24 to 28, whereas the C t values for Pappa2 ranged from 16 to 19. To estimate the copy number of each gene transcript in placenta samples, C t values were converted into Figure 1 Relative mRNA expression levels of (A) Pappa and (B) Pappa2 in mouse placenta (nZ6), liver (nZ3), kidney (nZ3), and stomach (nZ3). Values are expressed as estimates of cDNA copy number (calculated using standard curves described in text), and therefore comparison between genes assumes that reverse transcription reactions were equally efficient for Pappa and Pappa2. Each column represents the meanGS.D. copy number using standard curves constructed by plotting the log-transformed value of initial cDNA copy number (calculated from cDNA concentration) against its C t value. The r 2 values were 0 . 9951 for Pappa and 0 . 9933 for Pappa2, showing a strong correlation between C t values and copy number. The copy number of Pappa2 in the placenta was estimated to be nearly 1000-fold higher than that of Pappa (Pappa: 141G149 copies; Pappa2: 1 . 3!10 5 G0 . 7!10 5 copies). Because this analysis compares cDNA copy number, rather than mRNA copy number, this comparison assumes that the reverse transcription reaction was equally efficient for both Pappa and Pappa2.
Western blotting
Western blot analysis (Fig. 2) showed that PAPPA2 protein was strongly expressed in the murine placenta and to a lesser extent in the embryo, and that it was also detectable in murine pregnancy serum. It was not possible to use pseudopregnant females to test whether the placenta was the source of serum PAPPA2 in pregnant females because pseudopregnancy does not usually last until 12 . 5 dpc in mice ( Jasper et al. 2000 , Miller et al. 2004 . PAPPA2 protein was not detectable in nonpregnant mouse serum, liver, kidney, and stomach (Fig. 2) . The pattern of expression was similar in all tested mice.
In humans, PAPPA2 was detected in human serum during pregnancy at term (Fig. 3) and at lower levels during the first trimester (Fig. 4) , but not in serum from nonpregnant women (Figs 3 and 4) . The estimated size of PAPPA2 was w250 kDa in both mouse and human (Figs 2 and 3) , as found by Nishizawa et al. (2008) . In humans there was also a band of w130 kDa, which is close to the expected size of a splice variant of PAPPA2 (Page et al. 2001 ).
Localization of PAPPA2 in the placenta
The spatial and temporal expression pattern of PAPPA2 protein in the mouse placenta from gestational stages 10 . [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . 5 dpc was determined by immunohistochemistry.
The mouse placenta is composed of three main layers: a layer of decidual cells of maternal origin, the labyrinth of fetal origin, and the intermediate junctional zone. Throughout the stages examined, PAPPA2-positive signals were detected primarily in the junctional zone (Fig. 5) . Because we observed PAPPA2 expression in the junctional zone but not the decidua, we did not examine pseudopregnant controls, in which the junctional zone would not be present. At 11 . 5 dpc, IGFBP5 was expressed in the decidual part of the placenta, adjacent to PAPPA2 expression (Fig. 5) . In human placenta, PAPPA2 was clearly detectable in the syncytiotrophoblast layer of placental villi in the first trimester (see Supplementary  Figure 1 in the online version of the Journal of Endocrinology at http://joe.endocrinology-journals.org/cgi/content/full/ JOE-09-0136/DC1) and in invasive extravillous trophoblasts at the maternal-fetal interface (Fig. 6) . Whole-mount in situ hybridization of mouse embryo
At embryonic day 12 . 5, Pappa2 transcripts were found to be present in the nasal region, forebrain, dorsal side, and the sides of the tail (Fig. 7A and B) . To compare the expression of Pappa2 with that of its substrate, in situ hybridization was also carried out with Igfbp5 RNA probes. Igfbp5 transcripts were expressed throughout the body except in the brain region, developing whisker barrels and feet (data not shown), as found by Allan et al. (2000) . Igfbp5 expression in the tail occurred laterally and along the midline (Fig. 7C ). There was some co-expression of Pappa2 and Igfbp5 in the tail and nasal region. Igf-II was also found to be expressed in the tail, as well as the limbs (Fig. 7D) .
Discussion
In the present work, we show for the first time that Pappa2, but not Pappa, is highly expressed in the mouse placenta.
Pappa2 is expressed at much higher levels in the murine placenta than in other tissues analyzed, such as the kidney, stomach, and liver. Previously, Pappa2 expression was found to be higher in stomach than in a variety of other adult tissues, including brain, kidney, heart, lung, testis, pancreas, and prostate gland (Christians et al. 2006) . In humans, PAPPA2 has also been expressed much more strongly in placenta than in other adult tissues (Farr et al. 2000 , Page et al. 2001 . In contrast, while PAPPA is highly expressed in human placenta , Pappa expression in the murine placenta is not particularly high compared to other tissues (Qin et al. 2002 , Soe et al. 2002 . We quantitatively compared the transcript abundance of Pappa and Pappa2 in mouse placenta and found that Pappa2 levels were nearly 1000-fold higher than those of Pappa, as estimated by cDNA levels.
To identify specific sites of PAPPA2 expression, immunohistochemistry was performed in both mouse and human placentae. In the mouse, PAPPA2 is primarily expressed in the junctional zone, located between the maternal decidua and the fetal labyrinth zone. The junctional zone is mainly composed of two cell types: the spongiotrophoblasts and glycogen trophoblast cells (Coan et al. 2005) . Glycogen trophoblast cells have been proposed to be a specialized subtype of spongiotrophoblast, involved in the invasion of the decidua by fetal tissue (Adamson et al. 2002) . The substrate of PAPPA2, IGFBP5, is expressed in some maternal components of the mouse placenta, including endothelium of maternal blood vessels (Carter et al. 2006, this study) . Given that PAPPA2 contributes to the proteolysis of IGFBP5 (Overgaard et al. 2001) , its expression in the junctional zone likely leads to the breakdown of IGFBP5 in the neighboring decidua, freeing IGF-II. Similarly, in the human placenta, PAPPA2 is expressed in the syncytiotrophoblast layer of placental villi in the first trimester and may contribute to the release of IGF-II to promote feto-placental growth. In general, our results with human placenta confirm previous findings (Nishizawa et al. 2008 , Winn et al. 2009 ). However, using cell-specific markers to distinguish between trophoblasts and maternal decidual cells, we also observed some PAPPA2 immunoreactivity in invasive extravillous trophoblasts in the first trimester (at 12 weeks).
PAPPA2 is detectable in the circulation of pregnant women during the first trimester (Nishizawa et al. 2008; this study) raising the possibility that PAPPA2 may be a useful biomarker of placental dysfunction, as is the case with PAPPA. At least four recent studies have found PAPPA2 to be upregulated in hypertensive disorders of pregnancy including preeclampsia and HELLP syndrome (Buimer et al. 2008 , Nishizawa et al. 2008 , Sitras et al. 2009 , Winn et al. 2009 ). It is curious that, although PAPPA2 and PAPPA are proteases that cleave IGFBPs, upregulation of PAPPA2 is associated with disease, whereas abnormally low maternal serum levels of PAPPA are associated with a variety of pregnancy complications , Kwik & Morris 2003 , Dugoff et al. 2004 , Spencer et al. 2008 . The evaluation of PAPPA2 as a biomarker will require a better understanding of its physiological roles in the placenta, which will benefit from animal models (Sapin et al. 2001 , Cross 2003 . The parallels in the location of PAPPA2 expression between mouse and human found in this study indicate that the mouse will provide a suitable model.
Pappa2 is also expressed in mouse embryo. Using wholemount in situ hybridization, we found that Pappa2 is expressed in the tail and dorsal side of the embryo, forebrain, and the nasal region. While Pappa is present throughout the embryonic tail , Pappa2 transcripts are laterally located in the tail and the dorsal side of the embryo. The substrate of PAPPA2, IGFBP5, has been found to be expressed in various embryonic tissue types, including the developing tail (Allan et al. 2000) , as confirmed in this study. The co-localization of PAPPA2 and IGFBP5 in certain embryonic tissues suggests that PAPPA2 may play a role in Figure 6 PAPPA2 expression in invasive extravillous trophoblasts at 12 weeks. Sections were initially immunostained for cytokeratin 18, a marker of trophoblasts, followed by destaining and restaining for vimentin, a marker of maternal decidual cells, or PAPPA2. As shown in section 1, cytokeratin-positive cells are vimentin-negative (indicated by line arrowheads), whereas cells displaying vimentin immunoreactivity did not show cytokeratin immunoactivity (indicated by solid arrowheads), confirming the specificity of cytokeratin as a trophoblast marker and no interference of initial cytokeratin staining on subsequent immunostaining. Most cytokeratin-positive cells displayed PAPPA2 immunosignals (indicated by line arrowheads), although some trophoblasts (indicated by solid arrowheads) lacked PAPPA2 immunoreactivity. modulating IGFBP5 bioavailability in the mouse fetus, potentially affecting prenatal growth. Previous work with mice has suggested that Pappa2 may play a role in postnatal growth; Pappa2 was identified as a candidate gene for a quantitative trait locus (QTL) affecting tail length, skeletal growth, and levels of circulating IGFBP5 in mice (Christians et al. 2006 , Christians & Senger 2007 . The localization of Pappa2 expression in the embryonic tail (this study) is consistent with the hypothesis that Pappa2 is the gene responsible for a QTL affecting tail length.
This study demonstrates that Pappa2 is highly expressed at the feto-maternal interface of mouse placenta, confirming that the mouse will likely be a useful model for understanding the role of PAPPA2 in placental physiology. Previous observations show that PAPPA2 is found at higher levels in pregnancies complicated by preeclampsia or HELLP syndrome, whereas PAPPA is found at lower levels in various pregnancy complications which indicate that these two proteins may play quite different physiological roles despite having similar biochemical actions. The development of PAPPA2 as an additional marker may therefore offer increased diagnostic power for identifying placental dysfunction and complications such as preeclampsia and IUGR, which have lasting health consequences for the mother and child.
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